Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)

A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG–ACRIN Cancer Research Group (E2511)

(2015) Taofeek K. Owonikoko et al.   LUNG CANCER

Rôle de la voie Sonic Hedgehog dans les cancers thoraciques

(2015) E. Giroux Leprieur et al.   REVUE DES MALADIES RESPIRATOIRES

Prognostic value of circulating tumor cells’ reduction in patients with extensive small-cell lung cancer

(2014) Nicola Normanno et al.   LUNG CANCER

IGF-1R Targeting Increases the Antitumor Effects of DNA-Damaging Agents in SCLC Model: An Opportunity to Increase the Efficacy of Standard Therapy

(2013) C. Ferte et al.   MOLECULAR CANCER THERAPEUTICS

A crucial requirement for Hedgehog signaling in small cell lung cancer

(2011) Kwon-Sik Park et al.   NATURE MEDICINE

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

(2010) A Gualberto et al.   BRITISH JOURNAL OF CANCER

Cancer Stem Cells and the Ontogeny of Lung Cancer

(2008) Craig D. Peacock et al.   JOURNAL OF CLINICAL ONCOLOGY

Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt

(2007) Juddi Yeh et al.   LUNG CANCER